About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Apoe
apolipoprotein E
MGI:88057
307 phenotypes from multigenic genotypes
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Ay/a
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * C57BL/6J * KK/TaJcl 		abnormal glomerular mesangium morphology J:177084
abnormal inflammatory response J:177084
abnormal kidney morphology J:177084
atherosclerotic lesions J:177084
decreased circulating adiponectin level J:177084
glomerulosclerosis J:177084
hyperglycemia J:177084
increased circulating cholesterol level J:177084
increased circulating insulin level J:177084
increased circulating leptin level J:177084
increased circulating triglyceride level J:177084
increased monocyte cell number J:177084
insulin resistance J:177084
obese J:177084
Ay/a
Apoetm1Unc/Apoetm1Unc
Ccr2tm1Mae/Ccr2tm1Mae
involves: 129P2/OlaHsd * C57BL/6J * KK/TaJcl 		decreased circulating adiponectin level J:177084
normal homeostasis/metabolism phenotype J:177084
increased circulating cholesterol level J:177084
increased circulating leptin level J:177084
Abca1tm1Jdm/Abca1tm1Jdm
Abcg1tm1Dgen/Abcg1tm1Dgen
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * C57BL/6 * DBA * DBA/1LacJ 		abnormal hematopoietic system physiology J:190966
Albq4A/J/Albq4A/J
Apoetm1Unc/Apoetm1Unc
involves: A/J * C57BL/6J 		albuminuria J:135073
Albq4A/J/Albq4C57BL/6J
Apoetm1Unc/Apoetm1Unc
involves: A/J * C57BL/6J 		albuminuria J:135073
Angptl3tm1Lex/Angptl3tm1Lex
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6 		decreased circulating cholesterol level J:149912
decreased circulating triglyceride level J:149912
Apoa2tm1Bres/Apoa2+
Apoetm1Bres/Apoetm1Bres
involves: 129P2/OlaHsd * 129S4/SvJae 		decreased circulating cholesterol level J:37250
Apoa2tm1Bres/Apoa2tm1Bres
Apoetm1Bres/Apoetm1Bres
involves: 129P2/OlaHsd * 129S4/SvJae 		decreased circulating cholesterol level J:37250
decreased circulating HDL cholesterol level J:37250
Apobtm1Sgy/Apobtm1Sgy
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 		increased body weight J:41510
increased circulating cholesterol level J:41510
increased circulating triglyceride level J:41510
increased circulating VLDL cholesterol level J:41510
increased susceptibility to atherosclerosis J:41510
Apobtm2Sgy/Apobtm2Sgy
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 		abnormal cholesterol homeostasis J:41510
decreased body weight J:41510
decreased circulating cholesterol level J:41510
decreased susceptibility to atherosclerosis J:41510
increased circulating HDL cholesterol level J:41510
increased circulating triglyceride level J:41510
increased circulating VLDL cholesterol level J:41510
increased circulating VLDL triglyceride level J:41510
Apobtm2Sgy/Apobtm2Sgy
Apoetm1Unc/Apoetm1Unc
Lepob/Lepob
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 		abnormal circulating cholesterol level J:133453
atherosclerotic lesions J:133453
decreased circulating HDL cholesterol level J:133453
hyperglycemia J:133453
hypertension J:133453
impaired glucose tolerance J:133453
increased circulating cholesterol level J:133453
increased circulating free fatty acids level J:133453
increased circulating insulin level J:133453
increased circulating triglyceride level J:133453
increased circulating VLDL cholesterol level J:133453
obese J:133453
Apobec1tm1Chan/Apobec1tm1Chan
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * 129S4/SvJae 		abnormal circulating cholesterol level J:48202
decreased circulating cholesterol level J:48202
increased circulating cholesterol level J:48202
increased circulating triglyceride level J:48202
Apobec1tm1Ishi/Apobec1tm1Ishi
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 		decreased circulating cholesterol level J:41982
increased circulating triglyceride level J:41982
Apobec1tm1Rub/Apobec1tm1Rub
Apoetm1(APOE*2)Mae/Apoetm1(APOE*2)Mae
involves: 129P2/OlaHsd * C57BL/6 		decreased circulating cholesterol level J:79196
decreased circulating LDL cholesterol level J:79196
increased circulating HDL cholesterol level J:79196
increased circulating triglyceride level J:79196
increased circulating VLDL triglyceride level J:79196
Apoc1tm2Lmh/Apoc1tm2Lmh
Apoetm1Bres/Apoetm1Bres
involves: 129P2/OlaHsd * C57BL/6 		abnormal cholesterol homeostasis J:28261
increased circulating cholesterol level J:28261
ApoeTg(rtTA)1Gaga/ApoeTg(rtTA)1Gaga
Igs7tm1(tetO-Apoe)Gaga/0
involves: 129S1/Sv * C57BL/6J 		increased circulating cholesterol level J:136987
increased susceptibility to atherosclerosis J:136987
Apoetm1(APOE*2)Mae/Apoetm1(APOE*2)Mae
involves: 129P2/OlaHsd * C57BL/6 		abnormal Bruch membrane morphology J:101147
abnormal lipid homeostasis J:48565, J:67282
abnormal lipid level J:48565, J:67282
abnormal retina pigment epithelium morphology J:101147
atherosclerotic lesions J:48565
hyperlipidemia J:48565
increased circulating cholesterol level J:48565, J:67282
increased circulating triglyceride level J:48565, J:67282
increased susceptibility to atherosclerosis J:48565
normal liver/biliary system phenotype J:48565
retina degeneration J:101147
xanthoma J:48565
Apoetm1(APOE*2)Mae/Apoetm1(APOE*2)Mae
Ldlrtm1(LDLR)Mae/Ldlr+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 		abnormal lipid homeostasis J:67282
decreased susceptibility to hyperlipidemia J:67282
Apoetm1(APOE_i4)Sfu/Apoetm1(APOE_i4)Sfu
involves: 129P2/OlaHsd 		abnormal circulating cholesterol level J:104859
abnormal plasma membrane morphology J:103515
abnormal response to CNS ischemic injury J:104859
Apoetm1(APOE_i4)Sfu/Apoetm1(APOE_i4)Sfu
involves: 129P2/OlaHsd * C57BL/6N 		abnormal brain morphology J:60590
abnormal phospholipid level J:60590
decreased brain cholesterol level J:60590
increased circulating cholesterol level J:60590
increased circulating LDL cholesterol level J:60590
increased circulating VLDL cholesterol level J:60590
Apoetm1(APOE_i4)Sfu/Apoetm1(APOE_i4)Sfu
Tg(APPSWE)2576Kha/0
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * SJL 		normal homeostasis/metabolism phenotype J:121533
Apoetm1Bres/Apoetm1Bres
Bcl2tm1Irt/Bcl2tm1Irt
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6 		atherosclerotic lesions J:144243
normal cardiovascular system phenotype J:144243
normal homeostasis/metabolism phenotype J:144243
increased macrophage apoptosis J:144243
Apoetm1Bres/Apoetm1Bres
C6Q0/C6Q0
involves: 129P2/OlaHsd 		decreased susceptibility to atherosclerosis J:158457
Apoetm1Bres/Apoetm1Bres
Cd59atm1Bpm/Cd59atm1Bpm
involves: 129 * 129P2/OlaHsd 		increased susceptibility to atherosclerosis J:158457
vascular smooth muscle hyperplasia J:158457
vascular smooth muscle hypoplasia J:158457
Apoetm1Bres/Apoetm1Bres
Cx3cr1tm1Ifc/Cx3cr1tm1Ifc
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 		decreased susceptibility to atherosclerosis J:81822
impaired macrophage chemotaxis J:81822
Apoetm1Bres/Apoetm1Bres
Esr1tm1Ksk/Esr1tm1Ksk
B6.129P2-Apoetm1Bres Esr1tm1Ksk 		abnormal circulating cholesterol level J:68574
atherosclerotic lesions J:68574
normal homeostasis/metabolism phenotype J:68574
increased susceptibility to atherosclerosis J:68574
uterus atrophy J:68574
Apoetm1Bres/Apoetm1Bres
Fn1tm1Bwg/Fn1tm1Bwg
involves: 129S4/SvJae * C57BL/6 		abnormal cholesterol homeostasis J:90917
decreased circulating VLDL cholesterol level J:90917
decreased susceptibility to atherosclerosis J:90917
Apoetm1Bres/Apoetm1Bres
Ifngr1tm1Agt/Ifngr1tm1Agt
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J 		abnormal apolipoprotein level J:40921
decreased susceptibility to atherosclerosis J:40921
increased circulating cholesterol level J:40921
increased circulating phospholipid level J:40921
Apoetm1Bres/Apoetm1Bres
Ltb4r1tm1Adl/Ltb4r1tm1Adl
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 		decreased susceptibility to atherosclerosis J:117166
Apoetm1Bres/Apoetm1Bres
Mapk8tm1Flv/Mapk8tm1Flv
involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6 		atherosclerotic lesions J:94044
Apoetm1Bres/Apoetm1Bres
Mapk9tm1Flv/Mapk9tm1Flv
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 		abnormal macrophage morphology J:94044
abnormal macrophage physiology J:94044
decreased susceptibility to atherosclerosis J:94044
increased macrophage derived foam cell number J:94044
Apoetm1Bres/Apoetm1Bres
Plautm1Mlg/Plautm1Mlg
involves: 129 * C57BL/6 		aortic elastic tissue lesions J:44387
decreased susceptibility to atherosclerosis J:44387
Apoetm1Bres/Apoetm1Bres
Plgtm1Jld/Plgtm1Jld
involves: 129P2/OlaHsd * C57BL/6 * NIH Black Swiss 		abnormal body weight J:42927
atherosclerotic lesions J:42927
decreased circulating HDL cholesterol level J:42927
premature death J:42927
Apoetm1Khw/Apoetm1Khw
Tg(Mx1-cre)29-4Her/0
B6.Cg-Apoetm1Khw Tg(Mx1-cre)29-4Her 		abnormal apolipoprotein level J:196923
abnormal circulating lipid level J:196923
hyperlipidemia J:196923
normal immune system phenotype J:196923
increased circulating cholesterol level J:196923
increased circulating VLDL cholesterol level J:196923
increased susceptibility to atherosclerosis J:196923
Apoetm1Khw/Apoetm1Khw
Tg(Mx1-cre)29-4Her/?
involves: 129S4/SvJae * C57BL/6 * SJL 		increased circulating cholesterol level J:75681
increased circulating LDL cholesterol level J:75681
increased circulating triglyceride level J:75681
increased circulating VLDL cholesterol level J:75681
Apoetm1Lmh/Apoetm1Lmh
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd * C57BL/6 		normal homeostasis/metabolism phenotype J:117317
increased circulating cholesterol level J:117317
increased circulating HDL cholesterol level J:117317
increased circulating LDL cholesterol level J:117317
increased circulating triglyceride level J:117317
Apoetm1Lmh/Apoetm1Lmh
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S7/SvEvBrd 		atherosclerotic lesions J:129557
increased susceptibility to atherosclerosis J:129557
Apoetm1Lmh/Apoetm1Lmh
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Tg(Mx1-cre)29-4Her/0
involves: 129S7/SvEvBrd * C57BL/6J * SJL 		abnormal circulating enzyme level J:90547
abnormal circulating protein level J:90547
decreased circulating cholesterol level J:90547
decreased circulating LDL cholesterol level J:90547
decreased circulating triglyceride level J:90547
decreased circulating VLDL cholesterol level J:90547
increased circulating cholesterol level J:117317
increased circulating factor VIII level J:90547, J:117317
increased circulating HDL cholesterol level J:117317
increased circulating LDL cholesterol level J:117317
increased circulating triglyceride level J:117317
increased circulating von Willebrand factor level J:90547
increased susceptibility to atherosclerosis J:90547
Apoetm1Rraf/Apoetm1Rraf
Tg(Mx1-cre)29-4Her/0
B6.Cg-Apoetm1Rraf Tg(Mx1-cre)29-4Her 		abnormal apolipoprotein level J:196923
abnormal circulating cholesterol level J:196923
decreased circulating VLDL cholesterol level J:196923
decreased susceptibility to atherosclerosis J:196923
hyperlipidemia J:196923
normal immune system phenotype J:196923
increased circulating cholesterol level J:196923
Apoetm1Unc/Apoe+
Tg(APPV717I)1130Kha/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N 		premature death J:43446
Apoetm1Unc/Apoe+
Cyp4f13Gt(OST14770)Lex/Cyp4f13Gt(OST14770)Lex
involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6 		decreased susceptibility to atherosclerosis J:289999
Apoetm1Unc/Apoetm1Unc
Arhgef26tm1.1Kbur/Arhgef26tm1.1Kbur
B6.Cg-Arhgef26tm1.1Kbur Apoetm1Unc 		decreased susceptibility to atherosclerosis J:195919
Apoetm1Unc/Apoetm1Unc
Ath29C57BL/6J/?
involves: 129P2/OlaHsd * C3H/HeJ * C57BL/6J 		increased susceptibility to atherosclerosis J:127711
Apoetm1Unc/Apoetm1Unc
Ath29C57BL/6J/Ath29C57BL/6J
involves: C3H/HeJ * C57BL/6J 		atherosclerotic lesions J:140288
Apoetm1Unc/Apoetm1Unc
Ath30C57BL/6J/Ath30C57BL/6J
involves: C3H/HeJ * C57BL/6J 		atherosclerotic lesions J:140288
Apoetm1Unc/Apoetm1Unc
Ath31C57BL/6J/Ath31C57BL/6J
involves: C3H/HeJ * C57BL/6J 		atherosclerotic lesions J:140288
Apoetm1Unc/Apoetm1Unc
Ath32C57BL/6J/Ath32C57BL/6J
involves: C3H/HeJ * C57BL/6J 		atherosclerotic lesions J:140288
Apoetm1Unc/Apoetm1Unc
Ath33C3H/HeJ/Ath33C3H/HeJ
involves: C3H/HeJ * C57BL/6J 		atherosclerotic lesions J:140288
Apoetm1Unc/Apoetm1Unc
Athsq3C3H/HeJ/Athsq3C3H/HeJ
involves: C3H/HeJ * C57BL/6J 		atherosclerotic lesions J:140288
Apoetm1Unc/Apoetm1Unc
Athsq3C57BL/6J/Athsq3C57BL/6J
involves: C3H/HeJ * C57BL/6J 		atherosclerotic lesions J:140288
Apoetm1Unc/Apoetm1Unc
Atictm1c(EUCOMM)Hmgu/Atictm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * C57BL/6N 		decreased circulating cholesterol level J:338121
decreased susceptibility to atherosclerosis J:338121
normal homeostasis/metabolism phenotype J:338121
increased circulating triglyceride level J:338121
Apoetm1Unc/Apoetm1Unc
Atictm1c(EUCOMM)Hmgu/Atictm1c(EUCOMM)Hmgu
X/Tg(Myh11-icre/ERT2)1Soff
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J * C57BL/6N * FVB/N 		decreased susceptibility to atherosclerosis J:338121
normal homeostasis/metabolism phenotype J:338121
Apoetm1Unc/Apoetm1Unc
Cath1C3H/HeJ/Cath1C57BL/6J
involves: C3H/HeJ * C57BL/6J 		increased susceptibility to atherosclerosis J:129301
Apoetm1Unc/Apoetm1Unc
Cath1C57BL/6J/Cath1C57BL/6J
involves: C3H/HeJ * C57BL/6J 		increased susceptibility to atherosclerosis J:129301
Apoetm1Unc/Apoetm1Unc
Cav1tm1Mls/Cav1tm1Mls
involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * SJL 		decreased susceptibility to atherosclerosis J:101788
increased circulating cholesterol level J:101788
increased circulating LDL cholesterol level J:101788
increased circulating triglyceride level J:101788
increased circulating VLDL cholesterol level J:101788
Apoetm1Unc/Apoetm1Unc
Cbstm1Unc/Cbstm1Unc
Tg(Mt1-CBS)25Waku/0
involves: 129P2/OlaHsd * C3H * C57BL/6 		decreased body weight J:168131
increased circulating homocysteine level J:168131
increased circulating methionine level J:168131
increased circulating tumor necrosis factor level J:168131
increased Ly6C high monocyte number J:168131
increased monocyte cell number J:168131
increased susceptibility to atherosclerosis J:168131
Apoetm1Unc/Apoetm1Unc
Ccr1tm1Gao/Ccr1tm1Gao
involves: 129P2/OlaHsd * 129S4/SvJae 		atherosclerotic lesions J:128063
increased interferon-gamma secretion J:128063
Apoetm1Unc/Apoetm1Unc
Ccr2tm1Ifc/Ccr2+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 		decreased susceptibility to atherosclerosis J:111471
Apoetm1Unc/Apoetm1Unc
Ccr2tm1Ifc/Ccr2tm1Ifc
B6.Cg-Apoetm1Unc Ccr2tm1Ifc 		decreased monocyte cell number J:153310
decreased susceptibility to atherosclerosis J:153310
Apoetm1Unc/Apoetm1Unc
Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 		decreased susceptibility to atherosclerosis J:111471
impaired macrophage chemotaxis J:111471
Apoetm1Unc/Apoetm1Unc
Ccr2tm1Ifc/Ccr2tm1Ifc
Cx3cl1tm1Lira/Cx3cl1tm1Lira
B6.Cg-Apoetm1Unc Cx3cl1tm1Lira Ccr2tm1Ifc 		decreased monocyte cell number J:153310
decreased susceptibility to atherosclerosis J:153310
Apoetm1Unc/Apoetm1Unc
Ccr5tm1Blck/Ccr5tm1Blck
involves: 129P2/OlaHsd * C57BL/6 		abnormal cytokine secretion J:128063
abnormal lymphocyte physiology J:128063
abnormal mononuclear phagocyte morphology J:128063
atherosclerotic lesions J:128063
decreased interferon-gamma secretion J:128063
decreased T cell number J:128063
increased interleukin-10 secretion J:128063
Apoetm1Unc/Apoetm1Unc
Ccr5tm1Kuz/Ccr5tm1Kuz
involves: 129P2/OlaHsd * C57BL/6 		abnormal cytokine secretion J:128063
abnormal lymphocyte physiology J:128063
abnormal mononuclear phagocyte morphology J:128063
abnormal vascular smooth muscle morphology J:128063
atherosclerotic lesions J:128063
decreased interferon-gamma secretion J:128063
decreased T cell number J:128063
increased interleukin-10 secretion J:128063
Apoetm1Unc/Apoetm1Unc
Cd36tm1Mfe/Cd36tm1Mfe
involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6 		abnormal lipid level J:61672
abnormal macrophage derived foam cell morphology J:61672
abnormal macrophage physiology J:61672
decreased circulating triglyceride level J:61672
decreased susceptibility to atherosclerosis J:61672
increased cholesterol level J:61672
increased growth rate J:61672
xanthoma J:61672
Apoetm1Unc/Apoetm1Unc
Cd44tm1Mak/Cd44+
B6.129P2-Cd44tm1Mak Apoetm1Unc 		decreased susceptibility to atherosclerosis J:72315
Apoetm1Unc/Apoetm1Unc
Cd44tm1Mak/Cd44tm1Mak
B6.129P2-Cd44tm1Mak Apoetm1Unc 		decreased susceptibility to atherosclerosis J:72315
Apoetm1Unc/Apoetm1Unc
Cdh18Tg(GFAP-APOE_i4)1Hol/0
B6.Cg-Apoetm1Unc Cdh18Tg(GFAP-APOE_i4)1Hol/J 		abnormal astrocyte physiology J:58019
Apoetm1Unc/Apoetm1Unc
Cdkn1atm1Tyj/Cdkn1atm1Tyj
B6.129-Apoetm1Unc Cdkn1atm1Tyj 		abnormal response/metabolism to endogenous compounds J:125247
abnormal vascular smooth muscle physiology J:125247
decreased susceptibility to atherosclerosis J:125247
decreased susceptibility to induced morbidity/mortality J:125247
delayed cellular replicative senescence J:125247
increased vascular smooth muscle cell proliferation J:125247
Apoetm1Unc/Apoetm1Unc
Clutm1Jakh/Clutm1Jakh
Tg(APPV717F)109Ili/Tg(APPV717F)109Ili
involves: 129P2/OlaHsd * 129S2/SvPas 		amyloid beta deposits J:107702
amyloidosis J:107702
increased cerebrospinal fluid amyloid beta 40 isoform level J:107702
increased cerebrospinal fluid amyloid beta 42 isoform level J:107702
Apoetm1Unc/Apoetm1Unc
Crptm1Hjf/Crptm1Hjf
B6.Cg-Crptm1Hjf Apoetm1Unc 		decreased circulating HDL cholesterol level J:170409
decreased circulating triglyceride level J:170409
increased circulating HDL cholesterol level J:170409
increased susceptibility to atherosclerosis J:170409
Apoetm1Unc/Apoetm1Unc
Csf1op/Csf1op
involves: 129P2/OlaHsd * C3HeB/Fe * C57BL/6 		decreased susceptibility to atherosclerosis J:40136
increased circulating cholesterol level J:40136
Apoetm1Unc/Apoetm1Unc
Cst3tm1Karl/Cst3tm1Karl
involves: 129S/SvEv * C57BL/6 		abnormal aorta elastic tissue morphology J:106879
abnormal aorta tunica media morphology J:106879
abnormal aortic arch morphology J:106879
abnormal enzyme/coenzyme activity J:106879
abnormal enzyme/coenzyme level J:106879
atherosclerotic lesions J:106879
vascular smooth muscle hyperplasia J:106879
Apoetm1Unc/Apoetm1Unc
Cx3cl1tm1Sgs/Cx3cl1tm1Sgs
B6.129-Apoetm1Unc Cx3cl1tm1Sgs 		decreased susceptibility to atherosclerosis J:95279
impaired macrophage chemotaxis J:95279
increased macrophage derived foam cell number J:95279
Apoetm1Unc/Apoetm1Unc
Cx3cr1tm1Zm/Cx3cr1+
B6.129-Apoetm1Unc Cx3cr1tm1Zm 		decreased susceptibility to atherosclerosis J:103047
Apoetm1Unc/Apoetm1Unc
Cx3cr1tm1Zm/Cx3cr1tm1Zm
B6.129-Apoetm1Unc Cx3cr1tm1Zm 		decreased susceptibility to atherosclerosis J:103047
Apoetm1Unc/Apoetm1Unc
Cxcl10tm1Adl/Cxcl10tm1Adl
B6.129-Cxcl10tm1Adl Apoetm1Unc 		abnormal aorta morphology J:166204
aortic aneurysm J:166204
decreased CD4-positive, alpha-beta T cell number J:166204
decreased susceptibility to atherosclerosis J:166204
dilated aorta J:166204
hematoma J:166204
impaired macrophage chemotaxis J:166204
increased susceptibility to induced aneurysm formation J:166204
increased susceptibility to induced morbidity/mortality J:166204
thoracic aorta aneurysm J:166204
Apoetm1Unc/Apoetm1Unc
Cyp4f13Gt(OST14770)Lex/Cyp4f13Gt(OST14770)Lex
involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6 		abnormal macrophage chemotaxis J:289999
decreased cholesterol level J:289999
decreased susceptibility to atherosclerosis J:289999
increased cholesterol efflux J:289999
Apoetm1Unc/Apoetm1Unc
Cyp19a1tm1Esi/Cyp19a1tm1Esi
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 		abnormal aorta bulb morphology J:184647
abnormal gonadal fat pad morphology J:184647
abnormal liver morphology J:184647
atherosclerotic lesions J:184647
decreased circulating HDL cholesterol level J:184647
decreased circulating insulin level J:184647
hypertension J:184647
impaired glucose tolerance J:184647
increased body weight J:184647
increased circulating C-reactive protein level J:184647
increased circulating cholesterol level J:184647
increased circulating glucose level J:184647
increased circulating interleukin-6 level J:184647
increased circulating LDL cholesterol level J:184647
increased circulating triglyceride level J:184647
increased circulating tumor necrosis factor level J:184647
increased circulating VLDL cholesterol level J:184647
increased fat cell size J:184647
increased liver weight J:184647
increased susceptibility to age-related hepatic steatosis J:184647
increased systemic arterial blood pressure J:184647
insulin resistance J:184647
Apoetm1Unc/Apoetm1Unc
Ddit3tm1.1Irt/Ddit3tm1.1Irt
Taglntm2(cre)Yec/Tagln+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J 		decreased susceptibility to atherosclerosis J:233223
normal homeostasis/metabolism phenotype J:233223
Apoetm1Unc/Apoetm1Unc
Dp(17Nfkbil1-Or2h1)1Cogr/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J 		decreased susceptibility to atherosclerosis J:190754
normal homeostasis/metabolism phenotype J:190754
Apoetm1Unc/Apoetm1Unc
Egr1tm1Jmi/Egr1tm1Jmi
involves: 129 * C57BL/6 		abnormal susceptibility to atherosclerosis J:96665
Apoetm1Unc/Apoetm1Unc
Fabp4tm1Brsp/Fabp4tm1Brsp
Fabp5tm1Hota/Fabp5tm1Hota
B6.Cg-Fabp4tm1Brsp Fabp5tm1Hota Apoetm1Unc 		decreased body weight J:102223
decreased circulating cholesterol level J:102223
decreased circulating glucose level J:102223
decreased circulating triglyceride level J:102223
decreased susceptibility to atherosclerosis J:102223
improved glucose tolerance J:102223
increased insulin sensitivity J:102223
normal mortality/aging J:102223
Apoetm1Unc/Apoetm1Unc
Faslpr/Faslpr
B6.Cg-Apoetm1Unc Faslpr 		abnormal aorta morphology J:121671
abnormal heart morphology J:121671
abnormal trabecular bone morphology J:121671
abnormal vascular endothelial cell morphology J:121671
atherosclerotic lesions J:121671
decreased autoantibody level J:121671
decreased bone mineral density J:121671
decreased bone mineral density of femur J:121671
decreased bone mineral density of vertebrae J:121671
decreased bone trabecula number J:121671
decreased CD4-positive, alpha-beta T cell number J:121671
decreased CD8-positive, alpha-beta T cell number J:121671
decreased circulating cholesterol level J:121671
decreased trabecular bone connectivity density J:121671
decreased trabecular bone thickness J:121671
decreased trabecular bone volume J:121671
enlarged lymph nodes J:121671
enlarged spleen J:121671
enlarged thymus J:121671
glomerulonephritis J:121671
normal hematopoietic system phenotype J:121671
increased anti-double stranded DNA antibody level J:121671
increased autoantibody level J:121671
increased IgG level J:121671
increased kidney apoptosis J:121671
increased renal glomerulus lobularity J:121671
increased renal tubule apoptosis J:121671
increased urine protein level J:121671
renal glomerular immunoglobulin deposits J:121671
renal glomerulus hypertrophy J:121671
Apoetm1Unc/Apoetm1Unc
Faslpr/Faslpr
MRL.Cg-Apoetm1Unc Faslpr 		increased anti-double stranded DNA antibody level J:133606
increased anti-nuclear antigen antibody level J:133606
increased autoantibody level J:133606
increased circulating cholesterol level J:133606
increased immunoglobulin level J:133606
increased susceptibility to atherosclerosis J:133606
increased susceptibility to systemic lupus erythematosus J:133606
Apoetm1Unc/Apoetm1Unc
Faslgld/Faslgld
B6.Cg-Faslgld Apoetm1Unc 		abnormal lymph node morphology J:91058
abnormal renal glomerulus morphology J:91058, J:200141
atherosclerotic lesions J:91058, J:200141
blood vessel inflammation J:91058
decreased circulating HDL cholesterol level J:91058
enlarged lymph nodes J:91058, J:200141
enlarged spleen J:91058
impaired macrophage phagocytosis J:91058
increased anti-nuclear antigen antibody level J:91058, J:200141
increased apoptosis J:91058
increased autoantibody level J:91058
increased circulating cholesterol level J:91058, J:200141
increased circulating LDL cholesterol level J:91058
increased circulating triglyceride level J:91058
increased circulating VLDL cholesterol level J:91058
increased IgG level J:91058
increased spleen weight J:91058, J:200141
increased susceptibility to atherosclerosis J:91058
increased T cell number J:91058
increased urine protein level J:91058
kidney inflammation J:200141
Apoetm1Unc/Apoetm1Unc
Fut4tm1Jbl/Fut4tm1Jbl
Fut7tm1Jbl/Fut7tm1Jbl
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 		atherosclerotic lesions J:102212
Apoetm1Unc/Apoetm1Unc
Gja5tm1Mchn/Gja5tm1Mchn
Tg(TIE2-lacZ)182Sato/0
involves: 129P2/OlaHsd * BALB/c * C57BL/6 		abnormal neutrophil physiology J:162224
alveolitis J:162224
normal cardiovascular system phenotype J:162224
increased susceptibility to atherosclerosis J:162224
Apoetm1Unc/Apoetm1Unc
Glg1Gt(RST092)Byg/Glg1+
B6J.129P2-Apoetm1Unc Glg1Gt(RST092)Byg 		atherosclerotic lesions J:226586
normal cardiovascular system phenotype J:226586
decreased macrophage cell number J:226586
impaired macrophage chemotaxis J:226586
increased collagen level J:226586
Apoetm1Unc/Apoetm1Unc
Gofm1C57BL/6J/?
involves: C3H/HeJ * C57BL/6J 		abnormal gonadal fat pad morphology J:115779
Apoetm1Unc/Apoetm1Unc
Gofm2C3H/HeJ/?
involves: C3H/HeJ * C57BL/6J 		abnormal gonadal fat pad morphology J:115779
Apoetm1Unc/Apoetm1Unc
Gofm2C57BL/6J/?
involves: C3H/HeJ * C57BL/6J 		abnormal gonadal fat pad morphology J:115779
Apoetm1Unc/Apoetm1Unc
Gofm3C57BL/6J/?
involves: C3H/HeJ * C57BL/6J 		abnormal gonadal fat pad morphology J:115779
Apoetm1Unc/Apoetm1Unc
Gofm4C3H/HeJ/?
involves: C3H/HeJ * C57BL/6J 		abnormal gonadal fat pad morphology J:115779
Apoetm1Unc/Apoetm1Unc
Hdl5C57BL/6J/Hdl5C57BL/6J
involves: C3H/HeJ * C57BL/6J 		increased circulating LDL cholesterol level J:129301
increased circulating VLDL cholesterol level J:129301
Apoetm1Unc/Apoetm1Unc
Hdlq19C57BL/6J/Hdlq19C57BL/6J
involves: C3H/HeJ * C57BL/6J 		increased circulating HDL cholesterol level J:129301
Apoetm1Unc/Apoetm1Unc
Hdlq86C3H/HeJ/?
involves: C3H/HeJ * C57BL/6J 		increased circulating HDL cholesterol level J:129301
increased circulating LDL cholesterol level J:129301
increased circulating VLDL cholesterol level J:129301
increased triglyceride level J:129301
Apoetm1Unc/Apoetm1Unc
Hdlq86C3H/HeJ/Hdlq86C3H/HeJ
involves: C3H/HeJ * C57BL/6J 		increased circulating HDL cholesterol level J:129301
increased circulating LDL cholesterol level J:129301
increased circulating VLDL cholesterol level J:129301
increased triglyceride level J:129301
Apoetm1Unc/Apoetm1Unc
Hdlq91C3H/HeJ/?
involves: C3H/HeJ * C57BL/6J 		increased circulating HDL cholesterol level J:129301
Apoetm1Unc/Apoetm1Unc
Hhipl1tm1a(KOMP)Wtsi/Hhipl1tm1a(KOMP)Wtsi
involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N 		decreased susceptibility to atherosclerosis J:280707
Apoetm1Unc/Apoetm1Unc
Hptm1Alev/Hptm1Alev
involves: 129 		abnormal macrophage chemotaxis J:134942
atherosclerotic lesions J:134942
Apoetm1Unc/Apoetm1Unc
Hsd11b1tm1Lex/Hsd11b1tm1Lex
B6.129-Hsd11b1tm1Lex Apoetm1Unc 		abnormal bone marrow cell physiology J:199430
abnormal cytokine secretion J:199430
abnormal macrophage derived foam cell morphology J:199430
normal behavior/neurological phenotype J:199430
normal cardiovascular system phenotype J:199430
decreased cholesterol level J:199430
decreased macrophage cell number J:199430
decreased susceptibility to atherosclerosis J:199430
decreased tumor necrosis factor secretion J:199430
normal growth/size/body region phenotype J:199430
hyperlipidemia J:199430
normal immune system phenotype J:199430
Apoetm1Unc/Apoetm1Unc
Ifngtm1Ts/Ifngtm1Ts
B6.129-Apoetm1Unc Ifngtm1Ts 		dilated aorta J:166204
increased body weight J:166204
increased susceptibility to induced aneurysm formation J:166204
increased susceptibility to induced morbidity/mortality J:166204
Apoetm1Unc/Apoetm1Unc
Il1r1tm1Imx/Il1r1tm1Imx
B6.129-Il1r1tm1Imx Apoetm1Unc 		abnormal blood vessel physiology J:148173
decreased circulating interleukin-6 level J:148173
decreased susceptibility to atherosclerosis J:148173
decreased systemic arterial blood pressure J:148173
increased vasoconstriction J:148173
increased vasodilation J:148173
Apoetm1Unc/Apoetm1Unc
Il1rntm1Dih/Il1rntm1Dih
involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6 		abnormal aorta elastic tissue morphology J:132570
abnormal coronary artery morphology J:132570
abnormal macrophage chemotaxis J:132570
normal cardiovascular system phenotype J:132570
decreased body weight J:132570
decreased circulating cholesterol level J:132570
premature death J:132570
Apoetm1Unc/Apoetm1Unc
Il10tm1Cgn/Il10tm1Cgn
involves: 129P2/OlaHsd * C57BL/6 		abnormal arterial thrombosis J:105858
abnormal blood coagulation J:105858
abnormal circulating cholesterol level J:105858
abnormal circulating cytokine level J:105858
decreased circulating VLDL cholesterol level J:105858
increased circulating interferon-gamma level J:105858
increased circulating interleukin-12 level J:105858
increased circulating LDL cholesterol level J:105858
increased susceptibility to atherosclerosis J:105858
Apoetm1Unc/Apoetm1Unc
Itgb3tm1Hyn/Itgb3tm1Hyn
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 		anemia J:83615
atherosclerotic lesions J:83615
decreased susceptibility to diet-induced obesity J:83615
increased susceptibility to induced morbidity/mortality J:83615
lung inflammation J:83615
postnatal lethality, incomplete penetrance J:83615
premature death J:83615
Apoetm1Unc/Apoetm1Unc
Klf15tm1Jain/Klf15tm1Jain
involves: 129P2/OlaHsd * 129X1/SvJ 		increased circulating cholesterol level J:203920
increased circulating triglyceride level J:203920
increased susceptibility to atherosclerosis J:203920
increased susceptibility to induced morbidity/mortality J:203920
Apoetm1Unc/Apoetm1Unc
Klf15tm2Jain/Klf15tm2Jain
Tg(Tagln-cre)1Jjl/0
involves: 129P2/OlaHsd * FVB/N 		blood vessel inflammation J:203920
normal homeostasis/metabolism phenotype J:203920
increased macrophage cell number J:203920
increased susceptibility to atherosclerosis J:203920
vascular smooth muscle hypoplasia J:203920
Apoetm1Unc/Apoetm1Unc
Lcattm1Hgc/Lcattm1Hgc
involves: 129P2/OlaHsd * C57BL/6 * DBA 		abnormal cholesterol homeostasis J:75567
abnormal circulating protein level J:75567
abnormal lipid homeostasis J:75567
normal homeostasis/metabolism phenotype J:75567
Apoetm1Unc/Apoetm1Unc
Ldlrtm1Her/Ldlrtm1Her
involves: 129P2/OlaHsd * 129S7/SvEvBrd 		increased circulating cholesterol level J:59491
Apoetm1Unc/Apoetm1Unc
Ldlrtm1Her/Ldlrtm1Her
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J 		abnormal impulse conducting system conduction J:95598
abnormal response to cardiac infarction J:95598
abnormal ST segment J:95598
abnormal synapse morphology J:43043
abnormal thrombosis J:95598
atherosclerotic lesions J:95598
decreased circulating troponin level J:95598
decreased myocardial infarct size J:95598
Apoetm1Unc/Apoetm1Unc
Leprdb/Leprdb
involves: 129P2/OlaHsd * C57BLKS/J 		abnormal retina morphology J:103714
abnormal retina vasculature morphology J:103714
Apoetm1Unc/Apoetm1Unc
Lgals3tm1Poi/Lgals3tm1Poi
involves: 129/Sv * C57BL/6 * SJL 		decreased susceptibility to atherosclerosis J:130923
increased circulating cholesterol level J:130923
Apoetm1Unc/Apoetm1Unc
Lipgtm1Tq/Lipgtm1Tq
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J 		atherosclerotic lesions J:93987
decreased susceptibility to atherosclerosis J:93987
increased circulating cholesterol level J:93987
increased circulating HDL cholesterol level J:93987
increased circulating LDL cholesterol level J:93987
increased circulating phospholipid level J:93987
increased circulating triglyceride level J:93987
increased circulating VLDL cholesterol level J:93987
Apoetm1Unc/Apoetm1Unc
Lpltm1Sem/Lpltm1Sem
involves: 129P2/OlaHsd 		abnormal circulating cholesterol level J:151434
abnormal circulating lipid level J:151434
abnormal vascular wound healing J:151434
hyperlipidemia J:151434
increased circulating cholesterol level J:151434
increased circulating triglyceride level J:151434
increased susceptibility to induced thrombosis J:151434
Apoetm1Unc/Apoetm1Unc
Mmp9tm1Tvu/Mmp9tm1Tvu
involves: 129P2/OlaHsd * 129S6/SvEvTac 		decreased macrophage cell number J:110044
decreased susceptibility to atherosclerosis J:110044
vascular smooth muscle hypoplasia J:110044
Apoetm1Unc/Apoetm1Unc
Msr1tm1Csk/Msr1tm1Csk
either: (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6J * ICR) or (involves: 129P2/OlaHsd * 129X1/SvJ * 129/Sv * ICR) 		atherosclerotic lesions J:39079
increased circulating cholesterol level J:39079
Apoetm1Unc/Apoetm1Unc
Nceh1tm1Ishi/Nceh1tm1Ishi
B6.129-Nceh1tm1Ishi Apoetm1Unc 		abnormal cholesterol homeostasis J:152385
increased susceptibility to atherosclerosis J:152385
Apoetm1Unc/Apoetm1Unc
Ncf1tm1Shl/Ncf1tm1Shl
involves: 129P2/OlaHsd * 129S2/SvPas 		abnormal descending thoracic aorta morphology J:123854
abnormal susceptibility to atherosclerosis J:154332
aortic aneurysm J:123854
decreased acute inflammation J:123854
decreased systemic arterial systolic blood pressure J:123854
Apoetm1Unc/Apoetm1Unc
Nck1tm1Paw/Nck1tm1Paw
Nck2tm3Paw/Nck2tm3Paw
Tg(Cdh5-cre/ERT2)1Rha/0
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 		decreased inflammatory response J:326659
decreased susceptibility to diet-induced aortic fatty streak lesions J:326659
Apoetm1Unc/Apoetm1Unc
Nfe2l2tm1Mym/Nfe2l2tm1Mym
involves: 129P2/OlaHsd * C57BL/6J 		abnormal aorta morphology J:143903
abnormal macrophage physiology J:143903
decreased susceptibility to atherosclerosis J:143903
increased circulating glucose level J:143903
increased circulating triglyceride level J:143903
oxidative stress J:143903
Apoetm1Unc/Apoetm1Unc
Nhdlq11C3H/HeJ/Nhdlq11C3H/HeJ
involves: C3H/HeJ * C57BL/6J 		increased circulating LDL cholesterol level J:129301
increased circulating VLDL cholesterol level J:129301
increased triglyceride level J:129301
Apoetm1Unc/Apoetm1Unc
Nhdlq11C3H/HeJ/Nhdlq11C57BL/6J
involves: C3H/HeJ * C57BL/6J 		increased circulating LDL cholesterol level J:129301
increased circulating VLDL cholesterol level J:129301
increased triglyceride level J:129301
Apoetm1Unc/Apoetm1Unc
Nhdlq12C3H/HeJ/Nhdlq12C57BL/6J
involves: C3H/HeJ * C57BL/6J 		increased circulating LDL cholesterol level J:129301
increased circulating VLDL cholesterol level J:129301
Apoetm1Unc/Apoetm1Unc
Nhdlq12C57BL/6J/Nhdlq12C57BL/6J
involves: C3H/HeJ * C57BL/6J 		increased circulating LDL cholesterol level J:129301
increased circulating VLDL cholesterol level J:129301
Apoetm1Unc/Apoetm1Unc
Nos2tm1Mrl/Nos2tm1Mrl
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 		atherosclerotic lesions J:64566
decreased cholesterol level J:64566
normal homeostasis/metabolism phenotype J:64566
increased body weight J:64566
Apoetm1Unc/Apoetm1Unc
Nos3tm1Plh/Nos3tm1Plh
B6.129-Nos3tm1Plh Apoetm1Unc 		aortic dissection J:103306
cardiac fibrosis J:103306
decreased cardiac muscle contractility J:103306
dilated heart left ventricle J:103306
increased heart left ventricle posterior wall thickness J:103306
increased mean systemic arterial blood pressure J:103306
increased susceptibility to atherosclerosis J:103306
increased susceptibility to induced aneurysm formation J:103306
thick interventricular septum J:103306
Apoetm1Unc/Apoetm1Unc
Nos3tm1Unc/Nos3tm1Unc
B6.129P2-Nos3tm1Unc Apoetm1Unc 		abnormal cardiovascular system morphology J:60670
abnormal renal glomerulus morphology J:60670
aortic sinus aneurysm J:60670
atherosclerotic lesions J:60670
decreased kidney weight J:60670
increased circulating creatinine level J:60670
increased susceptibility to atherosclerosis J:60670
increased systemic arterial systolic blood pressure J:60670
Apoetm1Unc/Apoetm1Unc
Npc1m1N/Npc1m1N
involves: 129P2/OlaHsd * BALB/c 		increased circulating VLDL cholesterol level J:104996
Apoetm1Unc/Apoetm1Unc
Pecam1Gt(OST16303)Lex/Pecam1Gt(OST16303)Lex
B6.129-Apoetm1Unc Pecam1Gt(OST16303)Lex 		abnormal aorta endothelium morphology J:142083
atherosclerotic lesions J:142083
normal homeostasis/metabolism phenotype J:142083
Apoetm1Unc/Apoetm1Unc
Phactr1tm1.2Gdo/Phactr1tm1.2Gdo
B6.Cg-Apoetm1Unc Phactr1tm1.2Gdo 		normal cardiovascular system phenotype J:335230
increased heart rate J:335230
Apoetm1Unc/Apoetm1Unc
Pik3cgtm1Dwu/Pik3cgtm1Dwu
B6.Cg-Apoetm1Unc Pik3cgtm1Dwu 		atherosclerotic lesions J:121582
decreased circulating cholesterol level J:121582
Apoetm1Unc/Apoetm1Unc
Pla2g15tm1Ytan/Pla2g15tm1Ytan
involves: 129S/SvEv * B6.129P2-Apoetm1Unc/J 		abnormal macrophage morphology J:97471
atherosclerotic lesions J:97471
increased circulating cholesterol level J:97471
Apoetm1Unc/Apoetm1Unc
Pnhdlc1C57BL/6J/Pnhdlc1C57BL/6J
involves: C3H/HeJ * C57BL/6J 		increased circulating LDL cholesterol level J:129301
increased circulating VLDL cholesterol level J:129301
Apoetm1Unc/Apoetm1Unc
Pnhdlc6C3H/HeJ/?
involves: C3H/HeJ * C57BL/6J 		increased circulating LDL cholesterol level J:129301
increased circulating VLDL cholesterol level J:129301
Apoetm1Unc/Apoetm1Unc
Pon1tm1Lus/Pon1tm1Lus
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6J 		atherosclerotic lesions J:82696
oxidative stress J:82696
Apoetm1Unc/Apoetm1Unc
Ptgdrtm1Dgen/Ptgdrtm1Dgen
involves: 129P2/OlaHsd * C57BL/6 		increased cholesterol level J:192168
increased circulating cholesterol level J:192168
increased circulating triglyceride level J:192168
Apoetm1Unc/Apoetm1Unc
Rag2tm1Fwa/Rag2+
involves: 129P2/OlaHsd * 129S/SvEv 		abnormal aorta morphology J:59156
decreased body weight J:59156
decreased circulating cholesterol level J:59156
decreased circulating HDL cholesterol level J:59156
increased uterus weight J:59156
Apoetm1Unc/Apoetm1Unc
Rag2tm1Fwa/Rag2tm1Fwa
involves: 129P2/OlaHsd * 129S/SvEv 		abnormal aorta morphology J:59156
decreased body weight J:59156
decreased circulating cholesterol level J:59156
decreased circulating HDL cholesterol level J:59156
increased uterus weight J:59156
Apoetm1Unc/Apoetm1Unc
Scarb1tm1Kri/Scarb1tm1Kri
involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6 		abnormal coronary artery morphology J:201999
abnormal heart morphology J:201999
artery occlusion J:201999
atherosclerotic lesions J:201999
increased heart weight J:201999
premature death J:201999
Apoetm1Unc/Apoetm1Unc
Scarb1tm1Kri/Scarb1tm1Kri
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 		abnormal erythrocyte morphology J:75090
decreased hematocrit J:75090
decreased hemoglobin content J:75090
echinocytosis J:75090
hypochromic macrocytic anemia J:75090
macrocytosis J:75090
poikilocytosis J:75090
reticulocytosis J:75090
Apoetm1Unc/Apoetm1Unc
Serpind1tm1Moto/Serpind1+
involves: 129P2/OlaHsd * C57BL/6 * CBA 		abnormal urine nucleoside level J:122173
atherosclerotic lesions J:122173
oxidative stress J:122173
Apoetm1Unc/Apoetm1Unc
Serpine1tm1Mlg/Serpine1tm1Mlg
B6.129-Serpine1tm1Mlg Apoetm1Unc 		atherosclerotic lesions J:61287
increased circulating cholesterol level J:61287
Apoetm1Unc/Apoetm1Unc
Smarcd1tm1.1Jddl/Smarcd1tm1.1Jddl
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA 		abnormal bile salt homeostasis J:228944
decreased circulating cholesterol level J:228944
decreased susceptibility to atherosclerosis J:228944
Apoetm1Unc/Apoetm1Unc
Soat1tm1Far/Soat1tm1Far
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J 		abnormal brain morphology J:61147
abnormal cholesterol homeostasis J:61147
abnormal cholesterol level J:61147
abnormal coat appearance J:61147
abnormal dermal layer morphology J:61147
abnormal skin condition J:61147
abnormal skin morphology J:61147
atherosclerotic lesions J:61147
decreased circulating cholesterol level J:61147
decreased circulating VLDL cholesterol level J:61147
hyperkeratosis J:61147
skin fibrosis J:61147
skin inflammation J:61147
skin lesions J:61147
sparse hair J:61147
thick dermal layer J:61147
xanthoma J:61147
Apoetm1Unc/Apoetm1Unc
Soat2tm1Far/Soat2tm1Far
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J 		decreased circulating cholesterol level J:81836
decreased susceptibility to atherosclerosis J:81836
increased circulating HDL cholesterol level J:81836
increased circulating triglyceride level J:81836
increased phosphatidylcholine-sterol O-acyltransferase activity J:81836
Apoetm1Unc/Apoetm1Unc
Spp1tm1Blh/Spp1+
involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6J 		atherosclerotic lesions J:86531
Apoetm1Unc/Apoetm1Unc
Spp1tm1Blh/Spp1tm1Blh
involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6J 		abnormal macrophage physiology J:86531
decreased susceptibility to atherosclerosis J:86531
decreased susceptibility to induced aneurysm formation J:86531
Apoetm1Unc/Apoetm1Unc
Spp1tm1Rit/Spp1+
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 		decreased susceptibility to atherosclerosis J:103051
increased circulating cholesterol level J:103051
increased circulating triglyceride level J:103051
Apoetm1Unc/Apoetm1Unc
Spp1tm1Rit/Spp1tm1Rit
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 		calcified artery J:103051
decreased susceptibility to atherosclerosis J:103051
increased circulating cholesterol level J:103051
increased circulating triglyceride level J:103051
Apoetm1Unc/Apoetm1Unc
Sprr3tm1.1Ppy/Sprr3tm1.1Ppy
involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J * SJL 		abnormal vascular smooth muscle physiology J:230470
normal cardiovascular system phenotype J:230470
increased cellular sensitivity to hydrogen peroxide J:230470
increased susceptibility to atherosclerosis J:230470
vascular smooth muscle hypoplasia J:230470
Apoetm1Unc/Apoetm1Unc
Svep1em1Nost/Svep1em1Nost
involves: 129P2/OlaHsd * C57BL/6 		normal cardiovascular system phenotype J:304349
normal growth/size/body region phenotype J:304349
normal homeostasis/metabolism phenotype J:304349
Apoetm1Unc/Apoetm1Unc
Svep1tm1a(EUCOMM)Hmgu/Svep1+
involves: 129P2/OlaHsd * C57BL/6N 		abnormal artery morphology J:304349
normal growth/size/body region phenotype J:304349
normal homeostasis/metabolism phenotype J:304349
Apoetm1Unc/Apoetm1Unc
Svep1tm1c(EUCOMM)Hmgu/Svep1tm1c(EUCOMM)Hmgu
Tg(Myh11-icre/ERT2)1Soff/0
involves: 129P2/OlaHsd * C57BL/6N * FVB/N 		abnormal artery morphology J:304349
normal growth/size/body region phenotype J:304349
normal homeostasis/metabolism phenotype J:304349
Apoetm1Unc/Apoetm1Unc
Tg(APOC1)1Bres/0
involves: 129P2/OlaHsd * C57BL/6J * CBA/J 		atherosclerotic lesions J:80689
hyperlipidemia J:80689
impaired lipolysis J:80689
increased circulating cholesterol level J:80689
increased circulating LDL cholesterol level J:80689
increased circulating triglyceride level J:80689
increased circulating VLDL cholesterol level J:80689
increased circulating VLDL triglyceride level J:80689
increased lipoprotein lipase activity J:80689
increased triglyceride lipase activity J:80689
Apoetm1Unc/Apoetm1Unc
Tg(APPV717F)109Ili/0
involves: 129P2/OlaHsd * C57BL/6 		amyloid beta deposits J:127846, J:133058
Apoetm1Unc/Apoetm1Unc
Tg(APPV717F)109Ili/Tg(APPV717F)109Ili
involves: 129P2/OlaHsd 		amyloid beta deposits J:107702
increased cerebrospinal fluid amyloid beta 40 isoform level J:107702
increased cerebrospinal fluid amyloid beta 42 isoform level J:107702
Apoetm1Unc/Apoetm1Unc
Tg(APPV717F)109Ili/0
Tg(GFAP-APOE_i2)14Hol/0
involves: 129P2/OlaHsd * C57BL/6 * CBA 		amyloid beta deposits J:127846
Apoetm1Unc/Apoetm1Unc
Tg(APPV717F)109Ili/0
Tg(GFAP-APOE_i3)37Hol/0
involves: 129P2/OlaHsd * C57BL/6 * CBA 		amyloid beta deposits J:127846, J:133058
Apoetm1Unc/Apoetm1Unc
Tg(APPV717F)109Ili/0
Tg(GFAP-APOE_i4)#Hol/0
involves: 129P2/OlaHsd * C57BL/6 * CBA 		amyloid beta deposits J:127846, J:133058
Apoetm1Unc/Apoetm1Unc
Tg(APPV717I)1130Kha/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N 		premature death J:43446
Apoetm1Unc/Apoetm1Unc
Tg(CAG-IL1RN)1Cga/?
involves: 129P2/OlaHsd * C57BL/6 * DBA/1 * FVB 		decreased circulating serum amyloid protein level J:132570
decreased susceptibility to atherosclerosis J:132570
Apoetm1Unc/Apoetm1Unc
Tg(CAG-IL1RN)2Cga/?
involves: 129P2/OlaHsd * C57BL/6 * DBA/1 * FVB 		decreased circulating serum amyloid protein level J:132570
decreased susceptibility to atherosclerosis J:132570
Apoetm1Unc/Apoetm1Unc
Tg(CMV-Serpine1)1Dgi/0
B6.Cg-Apoetm1Unc Tg(CMV-Serpine1)1Dgi 		atherosclerotic lesions J:61287
increased circulating cholesterol level J:61287
Apoetm1Unc/Apoetm1Unc
Tg(EIF1AX-Aldh2*E487K)101Oht/Tg(EIF1AX-Aldh2*E487K)101Oht
B6.Cg-Apoetm1Unc Tg(EIF1AX-Aldh2*E487K)101Oht 		impaired spatial learning J:137374
Apoetm1Unc/Apoetm1Unc
Tg(Eno2-APOE_i3)1Rabr/0
involves: 129P2/OlaHsd * C57BL/6J * ICR 		abnormal nervous system physiology J:55835, J:100975
abnormal spatial learning J:100975
normal behavior/neurological phenotype J:100975
enhanced coordination J:100975
Apoetm1Unc/Apoetm1Unc
Tg(Eno2-APOE_i3)1Rabr/0
involves: 129P2/OlaHsd * ICR 		normal behavior/neurological phenotype J:101973
Apoetm1Unc/Apoetm1Unc
Tg(Eno2-APOE_i4)1Rabr/0
involves: 129P2/OlaHsd * C57BL/6J * ICR 		abnormal spatial learning J:100975
normal behavior/neurological phenotype J:100975
decreased vertical activity J:100975
normal nervous system phenotype J:55835
neurodegeneration J:55835, J:100975
Apoetm1Unc/Apoetm1Unc
Tg(Eno2-APOE_i4)1Rabr/0
involves: 129P2/OlaHsd * ICR 		abnormal dendrite morphology J:101973
increased anxiety-related response J:101973
increased startle reflex J:101973
Apoetm1Unc/Apoetm1Unc
Tg(Eno2-APP*751)10Cord/0
involves: 129P2/OlaHsd * C57BL/6 		gliosis J:133156
increased cerebral infarct size J:133156
Apoetm1Unc/Apoetm1Unc
Tg(Eno2-APP*751)10Cord/0
Cdh18Tg(GFAP-APOE_i4)1Hol/0
involves: 129P2/OlaHsd * C57BL/6 * CBA 		decreased cerebral infarct size J:133156
gliosis J:133156
Apoetm1Unc/Apoetm1Unc
Tg(Eno2-APP*751)10Cord/0
Tg(GFAP-APOE_i3)37Hol/0
involves: 129P2/OlaHsd * C57BL/6 * CBA 		decreased cerebral infarct size J:133156
gliosis J:133156
Apoetm1Unc/Apoetm1Unc
Tg(GFAP-APOE_i3)37Hol/0
B6.Cg-Apoetm1Unc Tg(GFAP-APOE_i3)37Hol 		abnormal fear/anxiety-related behavior J:71062
abnormal locomotor behavior J:71062
abnormal response to new environment J:71062
abnormal spatial learning J:71062
abnormal stationary movement J:71062
decreased startle reflex J:71062
Apoetm1Unc/Apoetm1Unc
Tg(GFAP-APOE_i3)37Hol/0
B6.Cg-Tg(GFAP-APOE_i3)37Hol Apoetm1Unc/J 		abnormal astrocyte physiology J:58019
abnormal axon extension J:93487
Apoetm1Unc/Apoetm1Unc
Tg(GFAP-APOE_i4)22Hol/0
B6.Cg-Apoetm1Unc Tg(GFAP-APOE_i4)22Hol 		abnormal axon extension J:93487
Apoetm1Unc/Apoetm1Unc
Tg(GFAP-APOE_i4)#Hol/0
B6.Cg-Apoetm1Unc Tg(GFAP-APOE_i4)#Hol 		abnormal locomotor behavior J:71062
abnormal response to new environment J:71062
abnormal spatial learning J:71062
abnormal stationary movement J:71062
decreased startle reflex J:71062
impaired spatial working memory J:71062
Apoetm1Unc/Apoetm1Unc
Tg(MSR1-Plau)1Ddi/0
involves: 129P2/OlaHsd * C57BL/6 * SJL 		abnormal artery morphology J:102208
abnormal heart morphology J:101486
artery occlusion J:101486, J:102208
enlarged heart J:101486
heart inflammation J:101486
increased susceptibility to atherosclerosis J:102208
increased susceptibility to induced morbidity/mortality J:102208
Apoetm1Unc/Apoetm1Unc
Tg(NOS3)2Crom/0
involves: 129P2/OlaHsd * C57BL/6 * FVB 		decreased circulating cholesterol level J:80701
decreased susceptibility to atherosclerosis J:80701
decreased systemic arterial blood pressure J:80701
Apoetm1Unc/Apoetm1Unc
Tg(NOS3)3Crom/0
involves: 129P2/OlaHsd * C57BL/6 * FVB 		decreased circulating cholesterol level J:80701
decreased susceptibility to atherosclerosis J:80701
decreased systemic arterial blood pressure J:80701
Apoetm1Unc/Apoetm1Unc
Tg(Prnp-Abca1)EHol/0
involves: 129P2/OlaHsd * C57BL/6 * CBA 		amyloid beta deposits J:131400
Apoetm1Unc/Apoetm1Unc
Thbdtm1.1(THBD)Sltz/Thbdtm1.1(THBD)Sltz
B6.129(FVB)-Thbdtm1.1(THBD)Sltz Apoetm1Unc 		abnormal enzyme/coenzyme activity J:191461
normal homeostasis/metabolism phenotype J:191461
Apoetm1Unc/Apoetm1Unc
Thbs4tm1Olsa/Thbs4tm1Olsa
involves: 129P2/OlaHsd * C57BL/6J 		normal homeostasis/metabolism phenotype J:345752
increased chemokine level J:345752
increased cholesterol level J:345752
increased circulating interleukin-10 level J:345752
increased circulating tumor necrosis factor level J:345752
increased macrophage cell number J:345752
Apoetm1Unc/Apoetm1Unc
Timp1tm1Pds/Y
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 		abnormal blood vessel physiology J:103082
Apoetm1Unc/Apoetm1Unc
Tlr4tm1Aki/Tlr4tm1Aki
involves: 129P2/OlaHsd * C57BL/6 		abnormal susceptibility to atherosclerosis J:91481
Apoetm1Unc/Apoetm1Unc
Tnfrsf11btm1Eac/Tnfrsf11btm1Eac
involves: 129S4/SvJaeSor * C57BL/6 		abnormal aorta morphology J:128053
abnormal brachiocephalic trunk morphology J:128053
atherosclerotic lesions J:128053
Apoetm1Unc/Apoetm1Unc
Tnfsf4Ath1-C57BL/6J/Tnfsf4Ath1-C57BL/6J
involves: C3H/HeJ * C57BL/6J 		atherosclerotic lesions J:140288
Apoetm1Unc/Apoetm1Unc
Trigq3C3H/HeJ/?
involves: C3H/HeJ * C57BL/6J 		increased triglyceride level J:129301
Apoetm1Unc/Apoetm1Unc
Trigq3C3H/HeJ/Trigq3C3H/HeJ
involves: C3H/HeJ * C57BL/6J 		increased triglyceride level J:129301
Apoetm1Unc/Apoetm1Unc
Trigq4C3H/HeJ/Trigq4C3H/HeJ
involves: C3H/HeJ * C57BL/6J 		increased triglyceride level J:129301
Apoetm1Unc/Apoetm1Unc
Trigq4C3H/HeJ/Trigq4C57BL/6J
involves: C3H/HeJ * C57BL/6J 		increased triglyceride level J:129301
Apoetm1Unc/Apoetm1Unc
Ttpatm1Far/Ttpa+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 		abnormal vitamin E level J:66419
atherosclerotic lesions J:66419
Apoetm1Unc/Apoetm1Unc
Ttpatm1Far/Ttpatm1Far
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 		abnormal lipid homeostasis J:66419
atherosclerotic lesions J:66419
Apoetm1Unc/Apoetm2(APOE_i3)Yhg
Zbtb20Tg(PDGFB-APPSwInd)20Lms/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 		amyloid beta deposits J:184138
Apoetm1Unc/Apoetm3(APOE_i4)Yhg
Zbtb20Tg(PDGFB-APPSwInd)20Lms/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 		amyloid beta deposits J:184138
Apoetm2(APOE*3)Mae/Apoetm2(APOE*3)Mae
B6.129P2-Apoetm2(APOE*3)Mae 		increased exploration in new environment J:139186
Apoetm2(APOE*3)Mae/Apoetm2(APOE*3)Mae
involves: 129P2/OlaHsd * C57BL/6 		abnormal retina pigment epithelium morphology J:101147
Apoetm2(APOE*3)Mae/Apoetm2(APOE*3)Mae
involves: 129P2/OlaHsd * C57BL/6J 		abnormal lipid homeostasis J:41705
abnormal lipid level J:41705
abnormal triglyceride level J:41705
atherosclerotic lesions J:48565
decreased circulating LDL cholesterol level J:41705
decreased circulating VLDL cholesterol level J:74417
decreased circulating VLDL triglyceride level J:74417
decreased interleukin-6 secretion J:86768
decreased susceptibility to atherosclerosis J:74417
decreased tumor necrosis factor secretion J:86768
increased circulating cholesterol level J:41705
increased circulating HDL cholesterol level J:74417
increased circulating triglyceride level J:74417
increased susceptibility to atherosclerosis J:41705
Apoetm2(APOE*3)Mae/Apoetm2(APOE*3)Mae
Ldlrtm1(LDLR)Mae/Ldlr+
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 		abnormal circulating lipid level J:146721
amyloid beta deposits J:146721
Apoetm2(APOE*3)Mae/Apoetm2(APOE*3)Mae
Tg(APPSWE)2576Kha/?
involves: 129P2/OlaHsd * C57BL/6 * SJL 		abnormal cerebrospinal fluid amyloid beta 40 isoform level J:98636
abnormal cerebrospinal fluid amyloid beta 42 isoform level J:98636
amyloid beta deposits J:98636
Apoetm2(APOE*3)Mae/Apoetm2(APOE*3)Mae
Tg(Thy1-APPSwDutIowa)BWevn/?
involves: 129P2/OlaHsd * C57BL/6 		abnormal astrocyte morphology J:136318
abnormal microglial cell morphology J:136318
amyloid beta deposits J:136318
Apoetm2(APOE_i2)Sfu/Apoetm2(APOE_i2)Sfu
involves: 129P2/OlaHsd 		abnormal response to CNS ischemic injury J:104859
decreased circulating cholesterol level J:104859
Apoetm3(APOE*4)Mae/Apoetm3(APOE*4)Mae
B6.129P2-Apoetm3(APOE*4)Mae 		abnormal spatial reference memory J:97643
abnormal spatial working memory J:97643
Apoetm3(APOE*4)Mae/Apoetm3(APOE*4)Mae
involves: 129P2/OlaHsd * C57BL/6 		abnormal Bruch membrane morphology J:101147
abnormal circulating lipid level J:151284
abnormal epididymal fat pad morphology J:151284
abnormal fat cell morphology J:151284
abnormal glucose homeostasis J:151284
abnormal lipid level J:74417
abnormal postnatal growth J:151284
abnormal response to infection J:138241
abnormal retina pigment epithelium morphology J:101147
amyloid beta deposits J:101147
cornea opacity J:138241
decreased circulating HDL cholesterol level J:74417
decreased circulating triglyceride level J:74417
impaired glucose tolerance J:151284
increased circulating VLDL cholesterol level J:74417
increased circulating VLDL triglyceride level J:74417
increased interleukin-6 secretion J:86768
increased susceptibility to atherosclerosis J:74417
increased tumor necrosis factor secretion J:86768
retina degeneration J:101147
retina neovascularization J:101147
retina pigment epithelium atrophy J:101147
thin retina outer nuclear layer J:101147
Apoetm3(APOE*4)Mae/Apoetm3(APOE*4)Mae
Ldlrtm1(LDLR)Mae/Ldlr+
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 		abnormal circulating lipid level J:146721
amyloid beta deposits J:146721
increased circulating cholesterol level J:146721
increased circulating triglyceride level J:146721
Apoetm3(APOE*4)Mae/Apoetm3(APOE*4)Mae
Tg(APPSWE)2576Kha/?
involves: 129P2/OlaHsd * C57BL/6 * SJL 		abnormal cerebrospinal fluid amyloid beta 40 isoform level J:98636
abnormal cerebrospinal fluid amyloid beta 42 isoform level J:98636
amyloid beta deposits J:98636
cerebral amyloid angiopathy J:98636
Apoetm3(APOE*4)Mae/Apoetm3(APOE*4)Mae
Tg(Thy1-APPSwDutIowa)BWevn/?
involves: 129P2/OlaHsd * C57BL/6 		abnormal astrocyte morphology J:136318
abnormal microglial cell morphology J:136318
amyloid beta deposits J:136318
Apoetm3(APOE_i3)Sfu/Apoetm3(APOE_i3)Sfu
involves: 129P2/OlaHsd 		abnormal response to CNS ischemic injury J:104859
decreased circulating cholesterol level J:104859
normal homeostasis/metabolism phenotype J:103515
Apoetm3(APOE_i3)Sfu/Apoetm3(APOE_i3)Sfu
Tg(APPSWE)2576Kha/0
involves: C57BL/6 * C57BL/6N * SJL 		normal homeostasis/metabolism phenotype J:121533
Soat1tm1Ishi/Soat1tm1Ishi
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 		abnormal dermal layer morphology J:63468
abnormal lipid homeostasis J:63468
abnormal skin condition J:63468
alopecia J:63468
decreased hair follicle number J:63468
dry eyes J:63468
increased circulating cholesterol level J:63468
Meibomian gland atrophy J:63468
mixed cellular infiltration to dermis J:63468
skin lesions J:63468
thick dermal layer J:63468
thick skin J:63468
xanthoma J:63468
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory